Rockefeller Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.62K Buy
370
+57
+18% +$1.22K ﹤0.01% 4265
2026
Q2
$5.75K Sell
313
-1,350
-81% -$21.8K ﹤0.01% 4203
2026
Q1
$32.5K Buy
1,663
+510
+44% +$15.1K ﹤0.01% 3480
2025
Q4
$35.9K Buy
1,153
+133
+13% +$3.65K ﹤0.01% 3226
2025
Q3
$22K Buy
+1,020
New +$18.4K ﹤0.01% 3314

Other funds holding VRDN

Rockefeller Capital Management's VRDN Position: Q3 2026 in Review

Rockefeller Capital Management increased its Viridian Therapeutics (VRDN) stake by 18% in Q3 2026, buying an estimated $1.22K and bringing the position to 370 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #4265.

Rockefeller Capital Management first reported a position in VRDN in Q3 2025 and has held it in 5 quarters since. The position peaked at $35.9K in Q4 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Rockefeller Capital Management held 370 shares of Viridian Therapeutics worth $7.62K as of Q3 2026.
  • Rockefeller Capital Management bought 57 Viridian Therapeutics shares in Q3 2026, an estimated $1.22K.
  • Viridian Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4265 holding.
  • Rockefeller Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Viridian Therapeutics position peaked at $35.9K in Q4 2025.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.